roscovitine; cell cycle; oligodendroglia; differentiation; apoptosis; rat cerebral cortex
Abstract :
[en] Since cyclin-dependent kinases (Cdks) and their endogenous inhibitors (Cdkis) play an essential role as regulators of cell cycle withdrawal and onset of differentiation within oligodendroglial cells, we assessed here the effects of exogenous chemical Cdk inhibitors (CKIs) on cultured rat cortical oligodendrocyte progenitor cells (OPCs). We showed that purine derivatives and especially roscovitine strongly inhibited OPCs proliferation. In the presence of mitogenic signals, roscovitine synergized with thyroid hormone to stimulate oligodendrocyte differentiation. Roscovitine also prevented oligodendroglial apoptosis induced by growth factor deprivation. We thus demonstrated that small molecular weight chemical CKIs have important effects on crucial events of oligodendroglial development in vitro. This might open prospects for using these apparently well tolerated agents in remyelination strategies. (C) 2003 ISDN. Published by Elsevier Ltd. All rights reserved.
Avellana-Adalid V., Nait-Oumesmar B., Lachapelle F., Baron-Van Evercooren A. Expansion of rat oligodendrocyte progenitors into proliferative "oligospheres" that retain differentiation potential. J. Neurosci. Res. 45:1996;558-570.
Belachew S., Malgrange B., Rigo J.-M., Rogister B., Leprince P., Hans G., Nguyen L., Moonen G. Glycine triggers an intracellular calcium influx in oligodendrocyte progenitor cells which is mediated by the activation of both the ionotropic glycine receptor and Na+-dependent transporters. Eur. J. Neurosci. 12:2000;1924-1930.
Belachew S., Aguirre A.A., Wang H., Vautier F., Yuan X., Anderson S., Kirby M., Gallo V. Cyclin-dependent kinase-2 controls oligodendrocyte progenitor cell cycle progression and is downregulated in adult oligodendrocyte progenitors. J. Neurosci. 22:2002;8553-8562.
Casaccia-Bonnefil P. Cell death in the oligodendrocyte lineage: a molecular perspective of life/death decisions in development and disease. Glia. 29:2000;124-135.
Durand B., Raff M. A cell-intrinsic timer that operates during oligodendrocyte development. Bioessays. 22:2000;64-71.
Edlund T., Jessell T.M. Progression from extrinsic to intrinsic signaling in cell fate specification: a view from the nervous system. Cell. 96:1999;211-224.
Ghiani C.A., Gallo V. Inhibition of cyclin E-cyclin-dependent kinase 2 complex formation and activity is associated with cell cycle arrest and withdrawal in oligodendrocyte progenitor cells. J. Neurosci. 21:2001;1274-1282.
Ghiani C.A., Eisen A.M., Yuan X., DePinho R.A., McBain C.J., Gallo V. Neurotransmitter receptor activation triggers p27(Kip1) and p21(CIP1) accumulation and G1 cell cycle arrest in oligodendrocyte progenitors. Development. 126:1999;1077-1090.
Hartwell L.H., Kastan M.B. Cell cycle control and cancer. Science. 266:1994;1821-1828.
King K.L., Cidlowski J.A. Cell cycle regulation and apoptosis. Annu. Rev. Physiol. 60:1998;601-617.
Knockaert M., Greengard P., Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 23:2002;417-425.
Louis J.C., Magal E., Muir D., Manthorpe M., Varon S. CG-4, a new bipotential glial cell line from rat brain, is capable of differentiating in vitro into either mature oligodendrocytes or type-2 astrocytes. J. Neurosci. Res. 31:1992;193-204.
Meijer L., Borgne A., Mulner O., Chong J.P., Blow J.J., Inagaki N., Inagaki M., Delcros J.G., Moulinoux J.P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243:1997;527-536.
Meijer L., Leclerc S., Leost M. Properties and potential-applications of chemical inhibitors of cyclin-dependent kinases. Pharmacol. Ther. 82:1999;279-284.
Morgan D.O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell. Dev. Biol. 13:1997;261-291.
Park D.S., Farinelli S.E., Greene L.A. Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons. J. Biol. Chem. 271:1996;8161-8169.
Sausville E.A., Zaharevitz D., Gussio R., Meijer L., Louarn-Leost M., Kunick C., Schultz R., Lahusen T., Headlee D., Stinson S., Arbuck S.G., Senderowicz A. Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target. Pharmacol. Ther. 82:1999;285-292.
Senderowicz A.M., Sausville E.A. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. 92:2000;376-387.
Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1999;1501-1512.
Shibata Y., Nishimura S., Okuyama A., Nakamura T. p53-Independent induction of apoptosis by cyclin-dependent kinase inhibition. Cell Growth Differ. 7:1996;887-891.
Shoshan Y., Nishiyama A., Chang A., Mork S., Barnett G.H., Cowell J.K., Trapp B.D., Staugaitis S.M. Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. Proc. Natl. Acad. Sci. U.S.A. 96:1999;10361-10366.
Yu C., Takeda M., Soliven B. Regulation of cell cycle proteins by TNF-alpha and TGF-beta in cells of oligodendroglial lineage. J. Neuroimmunol. 108:2000;2-10.
Zezula J., Casaccia-Bonnefil P., Ezhevsky S.A., Osterhout D.J., Levine J., Dowdy S.F., Chao M.V., Koff A. p21cip1 is required for the differentiation of oligodendrocytes independently of cell cycle withdrawal. EMBO Rep. 2:2001;27-34.
